6-氟吡啶甲酰胺 | 369-03-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氟吡啶甲酰胺
• 中文别名: 6-氟吡啶-2-甲酰胺
• 英文名称: 6-fluoropyridine-2-carboxamide
• 英文别名: 6-fluoro-pyridine-2-carboxylic acid amide；6-Fluor-pyridin-2-carbonsaeure-amid；2-fluoro-6-pyridine carboxamide
• CAS: 369-03-9
• 化学式: C₆H₅FN₂O
• 分子量: 140.117
• InChiKey: IKRHXEUDAFUUKD-UHFFFAOYSA-N

物化性质

• 熔点：
  134-137℃
• 沸点：
  287.9±25.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338,P304+P340,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
6-Fluoropyridine-2-carboxamide
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
6-Fluoropyridine-2-carboxamide
Ingredient name:
CAS number: 369-03-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H5FN2O
Molecular weight: 140.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氟吡啶甲酰胺 在 吡啶 、 potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.5h， 生成 N-[10,11-dichloro-4-oxo-3-(trifluoromethyl)-2,5,7-triazatricyclo[6.4.0.0²'⁶]dodeca-1(8),6,9,11-tetraen-3-yl]-6-[(3-methoxypropyl)amino]pyridine-2-carboxamide
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS
  [FR] NOUVEAUX COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE S100

  摘要：

  式（I）的化合物或其药用盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴（如RAGE、TLR4和EMMPRIN）之间相互作用的抑制剂，因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面是有用的。

  公开号：

  WO2015177367A1
• 作为产物：
  描述：

  2-氟吡啶-6-羧酸 在 N,N'-羰基二咪唑 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以95%的产率得到6-氟吡啶甲酰胺
  参考文献：
  名称：

  通过建立涉及酰亚胺接头的分子内氢键开发新型构象受限的选择性 Clk1/4 抑制剂

  摘要：

  作为前 mRNA 可变剪接的主要调节因子，发现不同的 Clk 同种型在各种肿瘤类型中过度表达，并且最近作为癌症治疗的潜在靶标受到了广泛关注。几项研究报告了有效的小分子 Clk1/4 抑制剂，具有良好的细胞抗癌活性；然而，它们的临床应用通常受到其对脱靶（主要是 Clk2 和 Dyrk1A）的选择性受损的阻碍。在这项研究中，我们提出了一系列新的N-芳酰化 5-甲氧基苯并噻吩-2-羧酰胺 (酰亚胺) 作为有效和选择性的 Clk1/4 抑制剂。发现该系列的效力主要取决于邻位之间存在分子内氢键-甲氧基和亚胺 NH，可稳定对 Clk1/4 的 ATP 结合口袋具有高亲和力的几乎共面的构象。该系列中最有效的两个产品，化合物20（4-氟-2-甲氧基）和31（5-氯-2-甲氧基）的无细胞 Clk1 IC 50分别为 4 和 9.7 nM，此外还具有前所未有的选择性与 Clk2 相比，对 Clk1 的亲和力分别高

  DOI：

  10.1016/j.ejmech.2022.114411

文献信息

• SIP3 antagonists
  申请人：Siena Biotech S.p.A.

  公开号：EP2878339A1

  公开（公告）日：2015-06-03

  The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.

  本发明涉及如下所述的S1P3受体拮抗剂（A）的公式及其药物组合物。公式（A）的化合物在制备药物方面非常有用，特别是用于治疗阿尔茨海默病。
• OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Braun Alain

  公开号：US20070149562A1

  公开（公告）日：2007-06-28

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及根据本文所定义的式（I）的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗或预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。
• S1P3 ANTAGONISTS
  申请人：SIENA BIOTECH S.P.A.

  公开号：US20160297762A1

  公开（公告）日：2016-10-13

  The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.

  本发明涉及如下所述的S1P3受体拮抗剂（A）的公式及其药物组合物。公式（A）的化合物在制备药物方面很有用，特别是用于治疗阿尔茨海默病。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Dillon Michael Patrick

  公开号：US20150191487A1

  公开（公告）日：2015-07-09

  Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R 1 is optionally substituted tetrazolyl, R 2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R 3 , R 4 , R 5 and R 6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X 3 and/or a P2X 2/3 receptor antagonist and methods of making the compounds.

  化合物的化学式I：或其药用可接受的盐，其中，R1是可选的取代的四氮唑基，R2是可选的取代的苯基，可选的取代的吡啶基或可选的取代的噻吩基，而R3、R4、R5和R6如本文所定义。还提供了使用这些化合物治疗与P2X3和/或P2X2/3受体拮抗剂相关的疾病的方法，以及制备这些化合物的方法。